The Artificial Intelligence & Cancers Association is the result of a unique public – private partnership that brings together the French National Cancer Institute (INCa), the Health Data Hub, the Health Industry Alliance for Research and Innovation (ARIIS), France Biotech and 9 of the world’s leading health industry companies in oncology.
Our ambition can be summed up in one sentence : to transform data into real innovations for patients. To achieve this ambition, the AI & Cancers Association is multiplying projects, testing national databases on industrial issues and working on their admissibility to regulatory authorities, in particular through a long-term dialogue with the French National Authority for Health (HAS).
The creation of this partnership between the public and private sectors demonstrates a shared will to accelerate cancer research and to make France a landmark ecosystem that is attractive at the global level.
The IA & Cancers Association supports each project leader from the ideation phase to the results. Projects are selected by our Board of Directors on the basis of three broad families of criteria : the innovative nature of the project, its potential for the national ecosystem and its contribution to the influence of the Association.
Projects may focus on rare, frequent, poor-prognosis or pediatric cancers, etc., and address issues related to patient journey, personalized medicine, search for new biomarkers…
For our third interview, it will be Nathalie Varoqueaux, Medical Director at AMGEN, who will answer our questions. You will discover why the global leader
For our second interview, Patrick Meshaka, Medical Director at Novartis, will answer our questions. You will discover why this laboratory has been present in health
Why did these industrialists choose to commit themselves to the industry? We interviewed several administrators with three questions. Here is the first interview in our
Filière Intelligence Artificielle & Cancers
